infectious diseases

News

Janssen axes hep C development with Achillion

Johnson & Johnson has ended a collaboration with US biotech Achillion to develop hepatitis C drugs, sending the US biotech firm's shares plummeting.

News

Regeneron ends development of RSV antibody

Regeneron dumps suptavumab after phase 3 trial failure.

News

Vernalis shares slide after latest FDA rejection

Shares in UK pharma Vernalis slid more than 15% after the US regulator rejected its cough and cold treatment, known as CCP-08.

News

Landmark HIV prophylaxis trial to begin next month

Trial involves generics supplied by Mylan.

News

Hepatitis Virus - 3d rendered illustration

AbbVie, Gilead target sick hepatitis C patients in EU

Competing hepatitis C combination drugs from AbbVie and Gilead are now approved in the EU, as the companies aim to treat patients who cannot be cured with established regimens.

News

Study backs HIV testing in GP surgeries in high-risk areas

GP surgeries should test new patients for HIV in areas of high prevalence as it is cost-effective, according to a new study.

Janssen axes hep C development with Achillion

Regeneron ends development of RSV antibody

Vernalis shares slide after latest FDA rejection

Landmark HIV prophylaxis trial to begin next month

AbbVie, Gilead target sick hepatitis C patients in EU

Study backs HIV testing in GP surgeries in high-risk areas

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

infectious diseases

Editor's Picks